Literature DB >> 32318505

Acanthamoeba encephalitis in immunocompetent hosts: A report of two cases.

Sohini Das1, Karthik Gunasekaran1, Sitara S R Ajjampur2, Dilip Abraham2, Tina George1, M Asisha Janeela1, Ramya Iyadurai1.   

Abstract

Acanthamoeba are ubiquitous free-living amoeba. Acanthamoeba infections cause necrotizing vasculitis, resulting in vessel thrombosis and cerebral infarction. Acanthamoeba CNS infections, though uncommon, are associated with high mortality. Diagnosis is difficult and often delayed. Here, we present two immunocompetent hosts with Acanthamoeba encephalitis with good outcomes. Copyright: © Journal of Family Medicine and Primary Care.

Entities:  

Keywords:  Acanthamoeba CNS infections; Acanthamoeba encephalitis; granulomatous amoebic encephalitis

Year:  2020        PMID: 32318505      PMCID: PMC7114032          DOI: 10.4103/jfmpc.jfmpc_1010_19

Source DB:  PubMed          Journal:  J Family Med Prim Care        ISSN: 2249-4863


Introduction

Acanthamoeba are free-living protozoa found in soil, dust, and water.[12] Active trophozoites have acanthopodia and feed on bacteria, yeast, and algae. Dormant cysts are seen during unfavorable environmental conditions.[3] Cyst wall has strong glycosidic linkages that impart resistance to disinfection.[24] Spectrum of disease includes keratitis, granulomatous encephalitis, meningoencephalitis, sinusitis, and skin lesions.[5678] Risk factors include Human Immunodeficiency Virus (HIV) infection, malignancy, immunosuppressant drugs, and history of organ transplant.[9] Acanthamoeba CNS infections are associated with high mortality.[1011] Here, we describe two immunocompetent patients with Acanthamoeba encephalitis.

Case History

Patient 1

A 51-year-old woman with no preexisting illnesses presented with high-grade fever and right-sided weakness for 4 days. She had history of falling into a well one month ago. Neck stiffness, hemiplegia, exaggerated deep tendon reflexes, and extensor plantar response on the right side were seen. The initial diagnosis was meningoencephalitis and we worked her up for various etiologies. Magnetic resonance imaging (MRI) brain revealed left middle cerebral arterial territory infarcts. CSF opening pressure, leucocyte count, and protein were elevated (27 cm water, 340 cells with 80% lymphocytes, and 86 mg/dl, respectively). In view of possible aspiration, CSF microscopy and culture (on nonnutrient agar with E. coli overlay) for Acanthamoeba was done. This was positive for Acanthamoeba cysts on day 4 [Figure 1]. CSF GeneXpert polymerase chain reaction (PCR) and mycobacteria growth indicator tube (MGIT) for Mycobacterium tuberculosis, bacterial, and fungal CSF cultures were negative. After positive Acanthamoeba culture report, combination therapy with rifampicin, fluconazole, and trimethoprim-sulfamethoxazole was initiated and planned for 6 weeks. At follow-up after one month of treatment, she was afebrile with residual right-sided hemiparesis.
Figure 1

Acanthamoeba cyst and trophozoite stages in CSF cultures from reported cases: (a) wet mount (400×) (b) calcofluor stain (400×) and (c) Giemsa stain (1000×) cyst in patient 1 and (d) trophozoites (400×) with acanthopodia (black arrow) in patient 2

Acanthamoeba cyst and trophozoite stages in CSF cultures from reported cases: (a) wet mount (400×) (b) calcofluor stain (400×) and (c) Giemsa stain (1000×) cyst in patient 1 and (d) trophozoites (400×) with acanthopodia (black arrow) in patient 2

Patient 2

A 22-year-old student presented with holocranial headache for 3 weeks. There was no history of fever, seizures, nasal discharge, loss of weight/appetite or aquatic activities. He had bilateral papilledema, without other neurological deficits. In this patient, we considered differential diagnoses of chronic meningitis, cerebral venous thrombosis and idiopathic intracranial hypertension. MRI brain was normal. CSF opening pressure was 28 cm water. CSF analysis showed two lymphocytes, with normal glucose and protein. CSF culture for bacteria, Mycobacteria (MGIT and GeneXpert PCR test) and fungi were negative. At this point, the possibility of Acanthamoeba infection was considered. CSF Acanthamoeba culture was positive on day 7 [Figure 1]. This patient was managed with fluconazole, trimethoprim-sulfamethoxazole, metronidazole, rifampicin, miltefosine for 3 months. A decline in CSF opening pressure and resolution of headache were seen. He was well at follow-up 6 months after completion of therapy. Both patients tested negative for HIV antibodies and had normal HbA1c levels.

Discussion

Acanthamoeba CNS infections are uncommon but frequently lethal. Acanthamoeba enter the body via inhalation/skin injuries followed by hematogenous dissemination and formation of cerebral ring-enhancing lesions.[12] Regions of brain involved include frontal, temporal, and parietal lobes, cerebellum, and corticomedullary junction.[13] Brain autopsy specimens show necrotizing vasculitis.[3] On microscopy, venulitis, trophozoites/cysts in perivascular spaces, meningoencephalitis with lymphocytic/histiocytic infiltrate, and granulomatous lesions have been noted.[3514] Though immunocompromised state is a risk factor, there are reports of severe disease in immunocompetent patients.[151617] Our first patient had history of fall into a freshwater body which may have led to the entry of Acanthamoeba. However, our second patient did not have similar history and was immunocompetent. There is limited data regarding prognostic factors, especially in immunocompetent hosts. We reviewed published cases of adult survivors (>15 years of age) of Acanthamoeba CNS infections from 1999 to 2019 indexed in Pubmed [Table 1]. 50% (4/8) were immunocompetent with no contact with water sources. However, Acanthamoeba are ubiquitous and history of no contact with water would not rule out infection. All survivors (8/8) received combination therapy and excision of brain lesions was done in 37% (3/8). Fluconazole was given in 62% (5/8), trimethoprim-sulfamethoxazole in 50% (4/8), and miltefosine and rifampicin in 37% (3/8).
Table 1

Selected Cases of Adult Survivors of Acanthamoeba Encephalitis in the last 20 years

First Author; Year of PublicationAge/gender*Immunocompromised state/risk factors-Yes/NoClinical featuresDiagnostic testImaging featuresTreatmentFollow-up after treatment completion
Sahly et al.[18]; 201738/MYes (HIV infection)Headacheamebic forms on H and E stain; positive CSF PCRRing-enhancing lesion on MRImiltefosine, fluconazole, trimethoprim-sulfamethoxazole, flucytosine for 7 months5 months
Webster et al.[16]; 201238/MNoTinnitus, seizuresBrain biopsy H and E stain and PCRTemporal lobe lesionSurgical excision; voriconazole, miltefosine; 3 months3 years
Lackner et al.[19];201017/MNoNM**CSFNMmeropenem, linezolid, moxifloxacin, fluconazoleNM
Sheng et al.[20]; 200963/MYes (h/o falling into ditch and aspirating water)Headache, vomitingCSF Wet-mount smear and Giemsa- trophozoites; CSF PCRCerebral lesions; leptomeningeal enhancementAmphotericin B, rifampicin; 4 weeksNM
Aichelburg et al.[21]; 200825/MNoFever, ataxia, cutaneous ulcersCSF Acanthamoeba PCRMultiple ring-enhancing lesions in cortex and brainstemTrimethoprim- sulfamethoxazole changed to sulfadiazine, fluconazole, miltefosine, amikacin; excision of cerebellar abscess2 years
Fung et al.[22]; 200741/MYes (Liver transplant, diabetes mellitus)Fever, seizuresFrontal lobectomy sample-cystsFrontal lobe lesionsSurgical excision, rifampicin, trimethoprim- sulfamethoxazole; 3 months11 years
Petry et al.[23]; 200664/FYes (Diabetes mellitus, mid-facial fracture)HeadacheCSF culturePneumatocelefluconazole, rifampin, metronidazole, sulfadiazine; 14 days.1 month
Hamide et al.[24]; 200245/FNoFever, signs of meningeal irritationCSF wet mount and GiemsaNormalRifampicin, fluconazole, trimethoprim- sulfamethoxazole, albendazole, ceftriaxone.1 year

*M: Male, F: Female; **NM: Not mentioned

Selected Cases of Adult Survivors of Acanthamoeba Encephalitis in the last 20 years *M: Male, F: Female; **NM: Not mentioned Challenges in management include reduced drug delivery across blood-brain barrier and lack of cysticidal action of drugs. Presenting features can mimic common diseases like cerebrovascular accident and tumors which makes early diagnosis difficult. Calcium-channel modulators and statins are being studied to look for anti-amoebic effects.[2526] Patients with meningoencephalitis should be asked about history of aquatic activities. However, negative history of contact with water bodies does not rule out CNS Acanthamoeba infections. Family medicine practitioners are often the first medical contact for such patients. Acanthamoebainfection should be suspected in patients with meningoencephalitis in whom no etiological organism has been found and those with multiple cerebral lesions. High index of suspicion among family medicine physicians may lead to better outcomes as early diagnosis and prompt initiation of therapy are crucial aspects of management.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  25 in total

1.  Fatal granulomatous amoebic encephalitis caused by Acanthamoeba in a newly diagnosed patient with systemic lupus erythematosus.

Authors:  Vamshi Krishna Thamtam; Megha S Uppin; Anjan Pyal; Subhash Kaul; Jyostna Y Rani; C Sundaram
Journal:  Neurol India       Date:  2016 Jan-Feb       Impact factor: 2.117

2.  Acanthamoeba meningoencephalitis in immunocompetent: A case report and review of literature.

Authors:  Vinay Khanna; Ba Shastri; G Anusha; Chiranjay Mukhopadhayay; Ruchee Khanna
Journal:  Trop Parasitol       Date:  2014-07

3.  Opportunistic free: Living amoeba now becoming a usual pathogen?

Authors:  Dnyaneshwari Purushottam Ghadage; Archana Chintaman Choure; Archana Bhimrao Wankhade; Arvind Vamanrao Bhore
Journal:  Indian J Pathol Microbiol       Date:  2017 Oct-Dec       Impact factor: 0.740

4.  Early diagnosis of Acanthamoeba infection during routine cytological examination of cerebrospinal fluid.

Authors:  Franz Petry; Michael Torzewski; Jürgen Bohl; Thomas Wilhelm-Schwenkmezger; Patrick Scheid; Julia Walochnik; Rolf Michel; Lothar Zöller; Konrad J Werhahn; Sucharit Bhakdi; Karl J Lackner
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

5.  Unexpected postmortem diagnosis of acanthamoeba meningoencephalitis in an immunocompetent child.

Authors:  Fariba Binesh; Mehran Karimi; Hossein Navabii
Journal:  BMJ Case Rep       Date:  2011-10-04

6.  First case of granulomatous amebic encephalitis caused by Acanthamoeba castellanii in Taiwan.

Authors:  Wang-Huei Sheng; Chien-Ching Hung; Huai-Hsuan Huang; Shih-Yu Liang; Yu-Jen Cheng; Dar-Der Ji; Shan-Chwen Chang
Journal:  Am J Trop Med Hyg       Date:  2009-08       Impact factor: 2.345

7.  Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.

Authors:  Carmen María Martín-Navarro; Jacob Lorenzo-Morales; Rubén P Machin; Atteneri López-Arencibia; José Manuel García-Castellano; Isabel de Fuentes; Brendan Loftus; Sutherland K Maciver; Basilio Valladares; José E Piñero
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

8.  Acanthamoeba meningoencephalitis.

Authors:  S R Chandra; Sikandar Adwani; Anitha Mahadevan
Journal:  Ann Indian Acad Neurol       Date:  2014-01       Impact factor: 1.383

9.  Effect of Cellulase Enzyme Treatment on Cyst Wall Degradation of Acanthamoeba sp.

Authors:  Tisha Lazuana; Hendri Astuty; Ika Puspa Sari
Journal:  J Parasitol Res       Date:  2019-03-28

Review 10.  Acanthamoeba in Southeast Asia - Overview and Challenges.

Authors:  Chooseel Bunsuwansakul; Tooba Mahboob; Kruawan Hounkong; Sawanya Laohaprapanon; Sukhuma Chitapornpan; Siriuma Jawjit; Atipat Yasiri; Sahapat Barusrux; Kingkan Bunluepuech; Nongyao Sawangjaroen; Cristina C Salibay; Chalermpon Kaewjai; Maria de Lourdes Pereira; Veeranoot Nissapatorn
Journal:  Korean J Parasitol       Date:  2019-08-31       Impact factor: 1.341

View more
  3 in total

1.  Recognition of Cell Wall Mannosylated Components as a Conserved Feature for Fungal Entrance, Adaptation and Survival Within Trophozoites of Acanthamoeba castellanii and Murine Macrophages.

Authors:  Marina da Silva Ferreira; Susana Ruiz Mendoza; Diego de Souza Gonçalves; Claudia Rodríguez-de la Noval; Leandro Honorato; Leonardo Nimrichter; Luís Felipe Costa Ramos; Fábio C S Nogueira; Gilberto B Domont; José Mauro Peralta; Allan J Guimarães
Journal:  Front Cell Infect Microbiol       Date:  2022-05-31       Impact factor: 6.073

2.  Granulomatous Amebic Encephalitis Presenting Like a Tumor-Chasing a Diagnostic Conundrum.

Authors:  Ashok V R Taallapalli; Saraswati Nashi; Girish B Kulkarni; Suvarna Alladi; Yasha T Chickabasaviah
Journal:  Ann Indian Acad Neurol       Date:  2021-10-07       Impact factor: 1.383

Review 3.  Drugs used for the treatment of cerebral and disseminated infections caused by free-living amoebae.

Authors:  Alexandre Taravaud; Zineb Fechtali-Moute; Philippe M Loiseau; Sébastien Pomel
Journal:  Clin Transl Sci       Date:  2021-03-01       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.